GSK and Sanofi Delay COVID-19 Vaccine

GlaxoSmithKline and Sanofi announced on Friday morning that clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year.

GlaxoSmithKline and Sanofi announced on Friday morning that clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year.

The two companies said they planned to start another study in two months, hoping to come up with a more effective vaccine by the end of next year. Shares in France’s Sanofi were down 2.8 percent, while Britain’s GSK was up 0.2 percent.

Sanofi said in a statement that results from Phase One and Phase Two trials showed “an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response in older adults likely due to an insufficient concentration of the antigen.”

While studies of the Phase Three trial were expected to start this month, Sanofi said it would instead launch a phase 2b study in February. “The study will include a proposed comparison with an authorized COVID-19 vaccine,” the company pointed out, declining to give further details.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.